

SenzaGen Q3 - A solid quarter

Redeye provides an update following SenzaGen's Q3 2024 report. We argue that the report is solid as the company continues increasing its sales and keeping costs at reasonable levels. We only make minor adjustments to our estimates and look forward to the Q4 report, which historically has been strong.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[SenzaGen Q3 - A solid quarter](#)